Microtest Laboratories will manufacture ImmusanT, Inc.’s Nexvax2 immunotherapeutic vaccine for its expected upcoming clinical trial. In addition to manufacturing Nexvax2, Microtest will provide a full range of testing services to ImmusanT, supporting drug product manufacture, including method transfer activities, complete final product release testing, storage and stability.
 
Nexvax2 is being investigated for the treatment of celiac disease, an inherited autoimmune disorder that is triggered by the consumption of foods containing gluten, causing an immune response resulting in inflammation of the small intestine. Safety, tolerability and bioactivity of Nexvax2 have been established in a Phase I clinical study.
 
“As a one-stop source of on-site pharmaceutical testing and manufacturing services, Microtest provides a fast, efficient, cost-effective — and risk-minimizing — alternative to subcontracting with a variety of providers at multiple locations,” said Alex Mello, director of Project Management, Microtest Laboratories. “We deliver the flexibility, solutions, and problem-solving experience manufacturers must have to ensure the most expeditious release of their product.”